Asthma – Trends and commercial aspect

Asthma – Trends and commercial aspects 

Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation

Based on deep dive analysis of the asthma market, it can be safely assumed that the asthma pipeline research to be one among the most active processes. There are almost 252 products that are in an active development in all the stages of the clinical research. There has been a significant breakthrough that is observed when innovation is considered. Based on existing market products, the compounds that are witnessing breakthrough are highly diverse in there mode of action.  Drug companies can take this as an opportunity and work on floating products that can offer advantage in various geographies.

As per a research, 50 first-in-class programs are identified in the asthma market. The programs are focused towards targeting 43 first-in-class molecular targets. 

Browse Complete Report With TOC: http://www.reportsandintelligence.com/frontier-pharma-asthma-identifying-and-commercializing-first-in-class-innovation-market

Almost 23% of the products with disclosed molecular targets are expected to witness the results of the latest innovations in the asthma market. These factors will act as very powerful drivers for the market and will lead big pharma companies to take full advantage of the prevailing opportunities in the segment. Despite high clinical trial attrition during research activities, the market study confirms that many of the first-in-class technologies will penetrate the market in the near future. The widespread adoption of these technologies will have a transforming effect in the clinical and commercial domains.

Biologics: a new wave in Asthma Treatment

 Small molecules are currently dominating the asthma market, accounting to approximately 99%.  The current trends in the asthma pipeline includes 64 biologics, adding to almost 24% of the overall in the pipeline products. Small molecules in themselves account to 178 compounds, adding to 66% of the drugs in the pipeline.

The numbers clearly suggest that there is a widespread acceptance, that is, both commercially and clinically to the development of biologics. The trend has an influence over other therapeutic areas such as oncology.  According to a finding, “Xolair (omalizumab), a recombinant humanized anti-IgE monoclonal Antibody (mAb), was the first humanized therapeutic mAb to be indicated for asthma. It was approved by the FDA in 2003 as an add-on therapy for adults and adolescents aged 12 and over, with moderate-to-severe allergic asthma and symptoms not adequately controlled with Inhaled Corticosteroids (ICS).”

Among the targeted therapies, Xolair is also one among the targeted therapy that was greatly successful in treating a specific asthma phenotype. The launch of this therapy had answers to many unmet needs for the treatment of asthma. It is estimated that almost 60% of the people suffering for asthma are allergic, and the use of Xolair can greatly benefit such patients. A very small part of the patient pool suffers from moderate to severe disease and needs to be treated.

Despite limited patient pool, the Xolair drug has managed to achieve a blockbuster status, and this status can be attributed to high annual cost of therapy (ACoT), and innovative drug development that meets the unmet needs. Aforementioned factors contribute to a strong commercial success of Xolair and make them a preferred choice among the suffering populace.    

The success of some isolated yet highly specific biologics are paving way for many such innovative drugs by thee drug developers. The target for highly specific biologics, aimed to meet specific needs might transform the way in which research is now conducted. Targeted drug therapies will benefit a specific patient population and also generate handsome revenue to the drug developers.

Prevailing Investment opportunities:

Based on statistical analysis, it is confirmed that 52 out of 59 first-in-class products are not in the process of licensing or in a co-development deal. Many promising therapies for asthma are in the pipeline and look to be potential therapeutic for asthma treatment. Therefore, successful innovations will be a great investing tool for stake holders and may prove profitable in the long run. The report covers significant strategic implication for biotech companies seeking out-license products and firms with in-licensing products. Both clinical and commercial prospects are dealt in detail to give strategic insights to the stake holders.

Explore more reports on Pharmaceuticals industry at: http://www.reportsandintelligence.com/pharmaceuticals-market-report